Psychobiology of Post-Traumatic Stress Disorder
Sunday, September 11, 2005 - Tuesday, September 13, 2005
Since the New York Academy of Sciences sponsored its 1996 conference on the psychobiology of post-traumatic stress disorder (PTSD) in New York City, there have been major research advances in the understanding and treatment of this disorder. Most of the biologic findings presented at the 1996 conference in extremely preliminary form have withstood the test of time and replication, and almost without exception, the researchers who presented at the previous conference are still active researchers in the field of PTSD. Research has undergone a dramatic improvement in the quality of findings—issues that appeared to be relatively simple ten years ago with only limited data available are now far more complex. However, strategies for examining the psychobiology of PTSD have allowed the field to keep pace with these complexities.
The conference will integrate basic science and clinical research, so that both bench researchers and clinicians can develop mutual understanding of recent progress in post-traumatic stress research. Attendees will achieve an understanding of molecular biology, pathophysiology, neurology, epidemiology, clinical care, and psychosocial management of PTSD.
We gratefully acknowledge the support of the National Institute of Mental Health and Pfizer Inc.
Rachel Yehuda, Bronx VA Medical Center and Mount Sinai School of Medicine
This is a CME-accredited program.
Goal and Objectives
The goal of the conference is to provide a forum for intensive discussion of recent developments in the field of the psychobiology of PTSD, wherein ramifications of advances in biological studies and their implication for improved treatment paradigms are explored.
At the conclusion of this CME activity, the participant should be able to:
- Describe the role of cognition and brain functioning in PTSD.
- Examine the efficacy of various treatment paradigms for PTSD.
- Identify genetic, developmental, and environmental contributions of PTSD etiology.
The target audience for this conference comprises clinicians—MDs, PhDs, RNs, and CSWs who are involved in the treatment of PTSD and in basic and clinical research into the basis and treatment of PTSD.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Mount Sinai School of Medicine and the New York Academy of Sciences.
Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mount Sinai School of Medicine designates this educational activity for a maximum of 17.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should only claim those credits that he/she actually spent in the activity.
Verification of attendance will be provided to all professionals.
Faculty Disclosure Policy
It is the policy of Mount Sinai School of Medicine to ensure fair balance, independence, objectivity, and scientific rigor in all of its sponsored activities. All faculty participating in sponsored activities are expected to disclose to the audience any real or apparent conflict of interest related to the content of their presentation, and any discussion of unlabeled or investigational use of any commercial product or device not yet approved in the United Stat